Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This multi-center, open-label, parallel-controlled, single-dose Phase 1 study is being
conducted to directly characterize the pharmacokinetic (PK) profiles and safety of Jaktinib
following administration of a single oral dose in subjects with varying degrees of hepatic
impairment compared to healthy matched control subjects with normal hepatic function(matched
by age, weight, and sex).